CAMBRIDGE, Mass.--(BUSINESS WIRE)--Judo Bio, a biotechnology company pioneering oligonucleotide medicines delivered to the kidney, today announced the presentation of preclinical data that demonstrate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback